Regulators, Not Pharma, Block Self‑Testing Experimental Therapies
The Enemy isn't Big Pharma. It's the FDA and Regulators who won't allow you to test experimental therapies on yourself (or your dog). Even if it's life or death.
Single Rapamycin Dose Boosts Brain Glucose, Cuts Synaptic Density
Single-dose rapamycin increases brain glucose metabolism but reduces synaptic density in Long-Evans rats [One week after intraperitoneal administration of rapamycin (8 mg/kg) 👨⚕️] https://t.co/6JhcZYS01h https://t.co/wruacgIvFM
Engineering Smarter, Healthier Babies Through Embryo Selection
The man engineering smarter, healthier babies before they're born: Jonathan Anomaly. This philosopher-turned-biotech founder says the future of your child's health starts at the embryo. Here are 9 things you need to know about embryo selection: https://t.co/XVQF5le4bE
Insulin-Like Peptide Trades Combat for Survival in Beetles
Insulin-like peptide has antagonistic pleiotropic effects on male combat traits and survival traits in an armed beetle https://t.co/7Re0I2vcDW
Minimally Invasive Clearing Media Enables Deep Live Brain Imaging
Isotonic and minimally invasive optical clearing media for live cell imaging ex vivo and in vivo "Here we develop minimally invasive optical clearing media for fluorescence imaging of live mammalian tissues.... SeeDB-Live minimally affects neuronal electrophysiological properties and sensory responses in...
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Turning Personal Loss Into Open Cancer Vaccine Platform
Paul's story developing a cancer vaccine for Rosie inspired me. I'm going to build something so that EVERYONE can do the same thing. My dog Lady died of hemagiosarcoma and I wish I'd been able to save her too ETA - hopefully a...
Drug Patents: Near-Term Generic Threat, Mid-Term Safeguards, Tirzepat
AI: Short-Term Cliffs (0-3 years remaining): Drugs like sacubitril/valsartan, dapagliflozin, pembrolizumab, ocrelizumab, daratumumab, and apixaban face imminent generic/biosimilar pressure Mid-Term Protection (4-7 years): Risankizumab and dupilumab have solid runway, supported by ongoing label expansions. Long-Term (8+ years): Tirzepatide's robust patents position it...
Micro-Cages Enable Precise Manipulation of Cell Clusters
These micro-cages are designed to hold and manipulate tiny cell clusters in miniaturized lab-on-a-chip devices. https://spectrum.ieee.org/lab-on-a-chip-grippers?share_id=9241061
First Human Age‑Reversal Trial Targets Whole‑Body Reset
The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...
FoxO3a Boost in Dentate Gyrus Eases Stress‑induced Depression
Overexpression of FoxO3a in the dentate gyrus alleviates CUS-induced anxiety- and depression-like behaviors and cognitive impairment https://t.co/p2t18NRkew
EpiAge‑R Integrates Epigenetic Clocks, Resilience, and Multi‑omics Ageing
Epigenetic Clocks, Resilience, and Multi-Omics Ageing: A Review and the EpiAge-R Conceptual Framework The hierarchical architecture of the EpiAge-R framework... https://t.co/YpwDdLI7wo https://t.co/Uid3kNzDHr
Adenine Methylation Forms New Linear Brain Aging Clock
A completely novel axis of epigenetic aging. N6-methyldeoxyadenosine (N6medA), i.e. NOT the usual 5 methyl cytosine, increases linearly with age in human prefrontal cortex (r=0.95). Genome-wide profiling reveals age-associated ADENINE methylation changes reminiscent of classic CpG based epigenetic clocks. Abdur...
Vaccination Boosts Survival in Multiple Myeloma Patients
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/L7r9caCcGN
MRD‑Negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Backs MRD as Early Endpoint for Myeloma Approvals
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/W3vwHRTzhE
Testing Ubiquitin Promoter for Stable Petunia Transformation
Alright, Alice 24-0001 petunia bits co-culturing with Agribacterium strain Gv3101 carrying a PcUBI4::RUBY::THSP construct. Testing out this ubiquitin promoter for stable transformation to avoid silencing. These will bake at 30°C until Monday and then transfered to selection. 🤞 https://t.co/SO1EKELMgU
Epigenetic Therapy Marks New Era in Glaucoma Treatment
Great to see ophthlamologists adopting epigenetic modifications and resets to treat eye diseases like glaucoma. A paradigm shift in medicine https://t.co/g2gr3WVpkf https://t.co/6gbBVHJuXI
Testing Parsley Promoter RUBY in Stable Petunia Transformation
Okee, two more cultivars to sterilize and transform and I'm done for the day. Let's rile up the agro and get this done. Also among the stuff I need to test for work, I'm going to see if this parsley...
Parsley Uniquitin Promoter Matches 35S at 72
Great signal at the 72hr mark which is peak RUBY accumulation. Parsley uniquitin promoter as reliable as 35s for my projects. Glory be. Here's the expired patent: https://t.co/njN84BkHho https://t.co/kDfx1RoenJ
China Biotech Receives FDA Approval for First Cell Therapy Trial
With FDA go ahead, a China #biotech notches a first in cell therapy testing https://t.co/QorwJmou8w by @realJacobBell $XENE $BHVN
Cancer Vaccines Show Promise for Hard-to-Treat Tumors
Cancer vaccines are showing marked efficacy vs refractory cancers and are going to be part of the future Rx armamentarium. Beyond that, ultimately, for prevention in high-risk individuals. A new stellar review @NatureMedicine https://t.co/PhtdZDtSBl https://t.co/okmwCD8AyB
Amyloid Antibody Therapy Triggers 100 Microhemorrhages in APOE4 Patient
100 brain microhemorrhages in a patient with cerebral amyloid angiopathy and 2 copies of APOE4 after amyloid antibody therapy https://t.co/ASpVuijFNW https://t.co/hdtwtv1usq
LAG‑3 Checkpoint Suffers Another Trial Setback, Focus Shifts
NEW: Another failure in the clinic in the world of LAG-3, a target once seen as possibly the next major checkpoint inhibitor after PD-1 and CTLA-4. My latest on Immutep's Phase 3 disappointment, as LAG-3 focus now shifts to a...
De Novo Enzymes Redefine Peptide Therapeutic Production
Peptide therapeutics are powerful. But making them has always been difficult. Traditional chemical synthesis can involve long routes, poor selectivity, and significant environmental impact, while biological production is often limited by the pathways evolution happened to provide. What if we could design...
HSV-1 Reactivation Linked to Faster Aging, Dementia
The reactivation of herpes simplex virus (HSV-1, not only herpes zoster) may be tied to accelerated aging and dementia, and account in part for the mechanism of Shingrix vaccine''s protection @WIRED https://t.co/iKF1JcYSu0
Gut Microbiome Proteins Influence Aging Speed, Metabolic Disease
Links between gut microbiome proteins and pace of aging, metabolic diseases, and medications @Cell_Metabolism https://t.co/Vg6vMPjnXm https://t.co/3SKNH6IEhJ
Biotech Layoffs Hit Evotec, Vistagen; Immutep Shares Plunge
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure https://t.co/OikmCdJ6sg $EVO $VTGN $IMMP - 81% $RARE $ATRA
Patients Should Drive Aggressive Immunotherapy Post-Remission
Merkel cell carcinoma log, day #594. Yesterday, I was at Dana-Farber for my first infusion of avelumab in more than 3 months. Aside from two botched blood tests — the buzz is the blood tests are being done with recently...
Key Challenges and Strategies for Conducting Ex‑US Trials
"Ex-US Clinical Trials: Tribulations, Preparations, and Expectations" - new From The Trenches blog from @ArthurTzianabos, CEO of Lifordi and seasoned drug developer, on the considerations for ex-US clinical trials... https://t.co/IZ6RUVKrZj
Correct Lung Target, Yet IMMP’s
Lung (not head & neck) was the right choice for $IMMP to pursue in phase 3, but it still failed. Stock -89%. Sory via @APEXONCO -> https://t.co/Y1ilGP5Aqq
Neuralink Patient Plays Online Games Hours After Surgery
Neuralink Patient Goes from Operating Room to Online Gaming in Hours by @cb_doge #EmergingTech #Innovation #Technology https://t.co/UaOCf4kTSC
CBD and CBG Reverse Fatty Liver in Mice
I teach medical students that fatty liver disease (MASLD) affects 1 in 3 adults and has limited approved drug treatments. That may be changing. Hebrew University researchers found CBD and CBG -- two non-psychoactive cannabis compounds -- reversed fatty liver in mice...
Market‑First Synthetic Biology: Validate Demand Before Scaling Science
When Erum Khan asked me why 80% of biotech companies fail at execution, I replied: "The majority of synthetic biology founders have become enamored with the tool, the technology that they developed and then they went out there with that hammer...
FDA Approves GSK Arexvy for At‑risk Adults 18‑49
#GSK Arexvy RSV Vaccine approved by US FDA with a wider indication for Adults aged 18 to 49 who are at increased risk of Lower Respiratory Tract Disease caused by RSV.
Jefferies Paints WVE Data as Win‑win‑win; Bear Sees Combo Role
Doing some reading ahead of the next wave of $WVE INHBE "body composition" 🙄 data, smirking at the Jefferies analyst set up, which basically frames 6-month data as a win-win-win for the stock price. His "bear case" "Bear case would still...
Sterile PES Filters Prove Effective for Algae Work
YES. My dumb idea of using sterile PES filters and/or their parchment slip covers for algae work seems to be workinggg. Gonna try to genegun these and tranafer the filter onto selective media once a recovery period passes. Was looking...
High‑fat Diet Pushes Gut Bacteria to Brain via Vagus
How to get bacteria to move from the gut into the brain? —eat a high-fat diet —vagus nerve is the conduit —in the mouse model https://t.co/BI6HIbVgPl
Eli Lilly Surges to #1 Pharma Sales in 2025
Another testimony of Eli Lilly’s increasing dominance in the BioTech and Pharma sector - compared to other Big Pharma companies - such as $PFE $JNJ $NVS $NVO $BMY $ABBV $MRK $SNY and others, can be seen in this excellent @NatRevDrugDisc...
New Cancer Interception Strategy Regresses Pancreatic Precancers
🆕 @ScienceMagazine An exciting new approach vs pancreatic cancer: "cancer interception" Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model https://t.co/erVtthSMjS https://t.co/2xHIYdIPrx
Low‑dose Rapamycin Eases Fatigue and PEM in ME/CFS
Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multisystem disorder characterized by profound fatigue… 👉 “Low-dose rapamycin effectively reduced PEM and other key...
FDA Reform Essential for Real Longevity Breakthroughs
I love the longevity proponents on X But we WON'T get true longevity therapeutics if we don't reform the FDA or find a way around them. The FDA is still a quagmire of regulatory rot that has to be reformed to get...
Lilly Warns GLP‑1 Knockoffs Are Dangerous, Intensifies Compounder Battle
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders https://t.co/XOKLqIzAES @ByJonGardner $LLY $NVO #obesity
Microbes in Tumors: Unraveling a Controversial Role
What is the significance of microbes in tumors, a field mired in controversy? https://t.co/D5sHkLLsrT https://t.co/ntGLlke4iC
RFK Jr Promotes Unproven Peptides, BPC‑157 Lacks Solid Data
RFK Jr is trying to get 14 peptides, without data on safety or efficacy, licensed and approved by FDA. His favorite is BPC-157. "Only three small human studies of BPC-157 exist, for instance, the largest of which is a telephone...
Top Resources for TF Binding, Enhancers, Histone Marks
8 Resources to study Transcription factor binding, enhancers and histone modification distribution 1. ENCODE https://t.co/N5hScyoAoP
Tropic Secures $105M to Mass‑produce Non‑browning Bananas
Tropic, a British gene-editing startup, has raised $105 million in new financing to expand production of bananas that don’t brown https://t.co/rHHAMO6mST
Pierre Fabre, ATRA to Meet FDA on Ebvallo CRL Soon
Pierre Fabre and $ATRA said FDA meeting to discuss the Ebvallo CRL has been scheduled. (Likely occuring within the next month.)
FDA Cracks Down on Misleading GLP‑1 Telehealth Marketing
The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them? Medical groups face ‘tricky’ questions when partners make misleading claims via @KatieMPalmer https://t.co/pf4Fwa7W7r
Join Final FDA Advisory Committee on Flu Shot Access
If you are curious about seeing what may be the last competent FDA advisory committee left standing in action as they contribute to determining access to flu shots next fall, join me, @jessicamalaty, & @SaveAmericaMvm at 12:30 pm ET on...
